Found: 8
Select item for more details and to access through your institution.
Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 2, p. 163, doi. 10.1007/s40261-021-01114-6
- By:
- Publication type:
- Article
Adverse Events with d-penicillamine Therapy in Hepatic Wilson's Disease: A Single-Center Retrospective Audit.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 2, p. 177, doi. 10.1007/s40261-022-01117-x
- By:
- Publication type:
- Article
Next-Generation Sequencing Liquid Biopsy-Guided Osimertinib Rechallenge in EGFR-Mutated Advanced Non-Small-Cell Lung Cancer Patients.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 2, p. 185, doi. 10.1007/s40261-021-01116-4
- By:
- Publication type:
- Article
Comparative Bioavailability Study of a New Vitamin D3 Orodispersible Film Versus a Marketed Oral Solution in Healthy Volunteers.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 2, p. 151, doi. 10.1007/s40261-021-01113-7
- By:
- Publication type:
- Article
Safety, Pharmacokinetics and Pharmacodynamics of DS-1040, in Combination with Thrombectomy, in Japanese Patients with Acute Ischemic Stroke.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 2, p. 137, doi. 10.1007/s40261-021-01112-8
- By:
- Publication type:
- Article
Opicapone for the Treatment of Parkinson's Disease "Off" Episodes: Pharmacology and Clinical Considerations.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 2, p. 127, doi. 10.1007/s40261-021-01109-3
- By:
- Publication type:
- Article
Informing and Empowering Patients and Clinicians to Make Evidence-Supported Outcome-Based Decisions in Relation to SGLT2 Inhibitor Therapies: The Use of the Novel Years of Drug administration (YoDa) Concept.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 2, p. 113, doi. 10.1007/s40261-021-01105-7
- By:
- Publication type:
- Article
Stepping Forward to the Next Level: Totality of Evidence for the First High-Concentration Adalimumab Biosimilar, CT-P17.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 2, p. 103, doi. 10.1007/s40261-021-01107-5
- By:
- Publication type:
- Article